Insilico Medicine has nominated ISM1354, an AI-designed small-molecule GIPR antagonist, as a preclinical candidate for obesity and type 2 diabetes. Across mice, rats, dogs and monkeys the compound showed oral bioavailability of 75–104%, at least 18-fold greater plasma exposure than an unnamed clinical-stage comparator at the same dose, and an approximately 45-fold margin of safety in early monkey toxicology. The rationale is pairing receptor blockade with GLP-1 therapy to preserve lean mass during fat loss, though no human has yet received the drug.
Key Points
- GIPR antagonist designed to preserve muscle alongside GLP-1 therapy
- 18-fold higher plasma exposure, 45-fold safety margin in monkeys
- All data preclinical and company-generated; comparator compound unnamed
Longevity Analysis
Lean mass retention is the central unresolved problem of pharmacological weight loss — skeletal muscle governs glucose disposal, mitochondrial capacity and functional independence across the later decades, and losing it alongside fat trades metabolic gain for structural decline. Blocking the GIP receptor rather than activating it represents a divergent mechanistic bet, with hepatic tolerability the recurring failure point that earlier candidates in this class could not clear. Using a liver injury prediction model to screen out hepatotoxic chemistry before synthesis is the more durable signal here: removing the liability early rather than managing it in the clinic.
Original published by Longevity.Technology, by Kyle Umipig.